Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

Open Label ◽

Bcg Therapy ◽

Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy

European Urology Supplements ◽

10.1016/s1569-9056(18)31563-x ◽

2018 ◽

Vol 17 (2) ◽

pp. e1050 ◽

Cited By ~ 5

Author(s):

C. Rentsch ◽

P. Bosshard ◽

G. Mayor ◽

M. Rieken ◽

H. Püschel ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Phase I ◽

Intravesical Instillation ◽

Invasive Bladder Cancer ◽

Open Label ◽

Bcg Therapy ◽

Muscle Invasive ◽

Recombinant Bcg

Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin VPM1002BC in patients with non-muscle invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2020.10.027 ◽

2020 ◽

Vol 38 (12) ◽

pp. 898

Author(s):

Cyrill A Rentsch ◽

George N Thalmann ◽

Ilaria Lucca ◽

Maciej Kwiatkowski ◽

Grégory J Wirth ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Maintenance Therapy ◽

Phase I ◽

Cancer Recurrence ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

Bladder Cancer Recurrence

A 2-week Maintenance Regimen of Intravesical Instillation of Bacillus Calmette-Guerin is Safe, Adherent and Effective in Patients with Non-muscle-invasive Bladder Cancer: A Prospective, Multicenter Phase II Clinical Trial

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hys097 ◽

2012 ◽

Vol 42 (9) ◽

pp. 813-819 ◽

Cited By ~ 5

Author(s):

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Phase Ii ◽

Intravesical Instillation ◽

Phase Ii Clinical Trial ◽

Invasive Bladder Cancer ◽

Multicenter Phase ◽

A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14

European Urology Oncology ◽

10.1016/j.euo.2021.12.006 ◽

2022 ◽

Author(s):

Cyrill A. Rentsch ◽

George N. Thalmann ◽

Ilaria Lucca ◽

Maciej Kwiatkowski ◽

Grégory J. Wirth ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Phase 1 ◽

Cancer Recurrence ◽

Invasive Bladder Cancer ◽

Bcg Therapy ◽

Muscle Invasive ◽

Bladder Cancer Recurrence

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Case Medical Research ◽

10.31525/ct1-nct04109092 ◽

2019 ◽

Author(s):

Keyword(s):

Bladder Cancer ◽

Invasive Bladder Cancer ◽

Bcg Therapy ◽

Faculty Opinions recommendation of Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739122585.793581022 ◽

2020 ◽

Author(s):

Otto Hemminki

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Bladder Cancer ◽

Invasive Bladder Cancer ◽

Repeat Dose ◽

Open Label ◽

A phase I open label dose‐escalation study to evaluate the tolerability, safety and immunological efficacy of sub‐urothelial durvalumab injection in adults with muscle‐invasive or high‐risk non‐muscle‐invasive bladder cancer (SUBDUE‐1, SUB‐urothelial DUrvalumab injection‐1 study): clinical trial protocol

BJU International ◽

10.1111/bju.15365 ◽

2021 ◽

Author(s):

Andrew Moe ◽

Elizabeth Liow ◽

Andrew Redfern ◽

Nicole Swarbrick ◽

Tom Ferguson ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

High Risk ◽

Phase I ◽

Trial Protocol ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose ◽

Phase I study of patients with non-muscle invasive bladder cancer (NMIBC) treated with vesigenurtacel-L (HS-410) after Bacillus Calmette-Guérin (BCG)

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-3-s2-p447 ◽

2015 ◽

Vol 3 (Suppl 2) ◽

pp. P447 ◽

Cited By ~ 1

Author(s):

Gary Steinberg ◽

Neal Shore ◽

Lawrence Karsh ◽

James Bailen ◽

Michael Woods ◽

...

Keyword(s):

Bladder Cancer ◽

Phase I ◽

Phase I Study ◽

Invasive Bladder Cancer ◽

1786 A PROSPECTIVE COMPARATIVE STUDY OF INTRAVESICAL BACILLUS CALMETTE-GUERIN (BCG) THERAPY WITH THE TOKYO OR CONNAUGHT STRAINS FOR NON-MUSCLE INVASIVE BLADDER CANCER

The Journal of Urology ◽

10.1016/j.juro.2013.02.2876 ◽

2013 ◽

Vol 189 (4S) ◽

Author(s):

Atsushi Sengiku ◽

Masaaki Ito ◽

Yu Miyazaki ◽

Harutake Sawazaki ◽

Takeshi Takahashi ◽

...

Keyword(s):

Bladder Cancer ◽

Comparative Study ◽

Invasive Bladder Cancer ◽

Bcg Therapy ◽

Prospective Comparative Study ◽

PD19-08 RADIOFREQUENCY-INDUCED THERMO-CHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE BCG THERAPY (HYMN): A OPEN-LABEL, MULTICENTRE, PHASE III RANDOMISED CONTROLLED TRIAL

The Journal of Urology ◽

10.1016/j.juro.2017.02.881 ◽

2017 ◽

Vol 197 (4S) ◽

Author(s):

Wei Shen Tan ◽

Laura Buckley ◽

Adam Devall ◽

Laurence Loubiére ◽

Ann Pope ◽

...

Keyword(s):

Bladder Cancer ◽

Controlled Trial ◽

Phase Iii ◽

Open Label ◽

Multicentre Phase ◽

Bcg Therapy ◽

Muscle Invasive ◽

Randomised Controlled